Hugo is about to joust da Vinci. It’s not a battle between Renaissance geniuses. Instead, a commercial fight is brewing ...

Weispfenning has more than 25 years of experience at Medtronic, joining its IR team 17 years ago. He led the function at the ...

Medtronic issues recall diabetes software affecting CareLink version 4.2B due to incorrect glucose data display, prompting clinician review.

Ryan Weispfenning has elected to take up the challenge of creating and leading the investor relations function at the planned ...

With the U.S. authorization for urologic procedures, “there is now choice” for hospitals that want to expand their robotic ...

Even if that will be an important step for Medtronic, Intuitive Surgical should remain the top player and still outpace its challenger. For one, it will take a long time for Medtronic's Hugo to earn ...

Salmon retired from Medtronic in September after a more than 20-year tenure at the medtech giant. Most recently, Salmon ...

Medtronic's fair value estimate has nudged higher to $111.05 from $109.82 as analysts grow more confident that the company ...

Medtronic plc is rated a Buy, expecting 10-11% annual total returns, supported by 7-8% EPS growth. Learn more about MDT stock ...

December 11, 2025—Medtronic announced that the Onyx liquid embolic system (LES)—Onyx 18 and Onyx 34—is now indicated in the United States for embolization of the middle meningeal artery (MMA) as an ...

Though the Medtronic OmniaSecure is the world's smallest defibrillation lead, the product development story isn't one of ...

Medtronic’s Hugo robotic surgery system earns FDA clearance, ending Intuitive’s long-held dominance and reshaping the future of soft-tissue robotics.